Trial Profile

APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fenretinide (Primary)
Indications Cystic fibrosis
Focus Adverse reactions; Therapeutic Use
Acronyms APPLAUD
Sponsors Laurent Pharmaceuticals

Most Recent Events

03 Nov 2022 Results published in the Laurent Pharmaceuticals Media Release.
03 Nov 2022 Primary endpoint has been met. (Absolute change in percent predicted forced expiratory volume in 1 second (FEV1%)), according to a Laurent Pharmaceuticals media release.
03 Nov 2022 According to a Laurent Pharmaceuticals media release, results from the study were presented at the North American Cystic Fibrosis Conference (NACFC) 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com